FTO-IN-3
CAS No. 2585198-87-2
FTO-IN-3( —— )
Catalog No. M28284 CAS No. 2585198-87-2
FTO-IN-3 is a FTO inhibitor that impair self-renewal in glioblastoma stem cells.
FTO-IN-3 is a FTO inhibitor that impair self-renewal in glioblastoma stem cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 295 | Get Quote |
|
10MG | 475 | Get Quote |
|
25MG | 761 | Get Quote |
|
50MG | 1017 | Get Quote |
|
100MG | 1377 | Get Quote |
|
200MG | 1782 | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameFTO-IN-3
-
NoteResearch use only, not for human use.
-
Brief DescriptionFTO-IN-3 is a FTO inhibitor that impair self-renewal in glioblastoma stem cells.
-
DescriptionFTO-IN-3 is a FTO inhibitor that impair self-renewal in glioblastoma stem cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorAntibacterial|S. aureus|E. coli
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2585198-87-2
-
Formula Weight258.3
-
Molecular FormulaC12H10N4OS
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (387.15 mM)
-
SMILESCOc(nc1)ncc1-c(cc1)cc2c1nc(N)s2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Alyar, S., et al. Quantitative structure–activity relationships studies for prediction of antimicrobial activity of synthesized disulfonamide derivatives. Med Chem Res 20, 175–183 (2011).
molnova catalog
related products
-
PBT-1033
PBT-1033(PBT-2) is a potential neuroprotective agent for the treatment of Alzheimer's disease and Huntington's disease.
-
(1,5E,11E)-tridecatr...
(1,5E,11E)-tridecatriene-7,9-diyne-3,4-diacetate is a natural product for research related to life sciences.
-
3-Epiursolic acid
3-Epiursolic acid may have antiinflammatory activity, it shows inhibition on Cathepsins L (catL), the IC50 value of 6.5 μM, cathepsins L (catL) and B play an important role in tumor progression and have been considered promising therapeutic targets in the development of novel anticancer agents.